Penumbra, Inc.
HealthcareNYSE:PEN · New York Stock Exchange
+$0.39 today
Vol 0.45M · Avg 0.50M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
12.4%
avg 3.5%
ROIC
9.9%
avg 2.7%
ROA
9.7%
avg 2.7%
Analysis
ROE is currently the strongest return metric at 12.4% versus its period average of 3.5%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Adam Elsesser | Co-Founder, Chairman & Chief Executive Officer | $851,620.00 | — | 64 | $683,042.00 | 1.74% |
Shruthi Narayan | President | $737,351.00 | — | 41 | $30,755.00 | 0.08% |
Maggie S. Yuen | Chief Financial Officer | $722,467.00 | — | 54 | $18,167.00 | 0.05% |
Johanna Roberts | Executive Vice President, General Counsel & Secretary | $722,371.00 | — | 54 | $67,298.00 | 0.17% |
Lambert Shiu | Chief Accounting Officer | $601,141.00 | — | 46 | $39,323.00 | 0.10% |
Arani Bose | Co-Founder & Director | $60,000.00 | — | 64 | $1,147.00 | <0.01% |
Ben Tompkins | Executive Vice President of Development & Compliance | — | — | — | — | — |
Ben Sorci | Executive Vice President of Operations | — | — | — | — | — |
Steve Chen | Director of Product Management | — | — | — | — | — |
Pankaj Tiwari | Executive Vice President & Chief Information Officer | — | — | — | — | — |
Cecilia E. Furlong | Director of Business Development | — | — | — | — | — |
Holly Sit | Director of Research & Development | — | — | — | — | — |
James F. Benenati FSIR | Chief Medical Officer | — | — | — | $413,131.00 | 1.05% |
Jason Richard Mills | Executive Vice President of Strategy | — | — | — | — | — |
Jee Hamlyn-Harris | Investor Relations Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
103
$39.26M
Net Sentiment
$39.26M
Net selling
Most Active
Roberts Johanna
48 transactions
1–10 of 103
Analysis
Insiders reported 0 buys worth $0.00 and 103 sells worth $39.26M over the last 12 months. That adds up to net selling of $39.26M. Roberts Johanna was the most active insider with 48 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +129.9% | +25.1% (13yr)2 analysts |
| Revenue | N/A | N/A | +43.6% | +17.5% (13yr)5 analysts |
| Net Income | N/A | N/A | +53.5% | +26.6% (13yr)5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Recent growth has been strongest in EPS at +129.9% over three years. Forward estimates point to Net Income at +26.6% (13yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
DaVita Inc.
NYSE:DVA
$13.40B
Align Technology, Inc.
NASDAQ:ALGN
$12.52B
Globus Medical, Inc.
NYSE:GMED
$10.84B
Baxter International Inc.
NYSE:BAX
$10.77B
Henry Schein, Inc.
NASDAQ:HSIC
$9.26B
Charles River Laboratories International, Inc.
NYSE:CRL
$9.03B
Bio-Rad Laboratories, Inc.
NYSE:BIO
$7.73B
HealthEquity, Inc.
NASDAQ:HQY
$7.39B
Hims & Hers Health, Inc.
NYSE:HIMS
$5.98B
Who manages PEN?
Penumbra, Inc. (PEN) lists 15 active executives. The top listed executive is Adam Elsesser, Co-Founder, Chairman & Chief Executive Officer.
Are PEN insiders buying or selling?
Recent insider activity shows net selling of $54.62M.
Explore More
Continue the stock analysis
Jump to another research area for this company.